ACP
BMY.RT

Ashfield Capital Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ashfield Capital Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,930
Closed -$39K – 229
2020
Q2 		$39K Sell
10,930
-762
-7% -$2.75K ﹤0.01% 214
2020
Q1 		$44K Sell
11,692
-5,239
-31% -$17.3K 0.01% 212
2019
Q4 		$51K Buy
+16,931
New +$44K 0.01% 232

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ashfield Capital Partners's BMY.RT Position: Q3 2020 in Review

Ashfield Capital Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 10,930 shares — an estimated $39K sold.

Ashfield Capital Partners first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $51K in Q4 2019. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Ashfield Capital Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Ashfield Capital Partners sold 10,930 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $39K.
  • Ashfield Capital Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Ashfield Capital Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $51K in Q4 2019.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Ashfield Capital Partners's 13F filing for Q3 2020, filed 3 Nov 2020.